Authors
1 Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran
2 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Cell and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract
Objective: Pseudocatalase/superoxide dismutase (PSD) is a topical gel considered
having therapeutic effects in vitiligo. This study was designed to evaluate the efficacy of
this combination in vitiligo.
Methods: This was a pilot randomized, double‑blind, placebo‑controlled trial on 46
symmetrical vitiligo lesions of limbs in 23 patients referring to dermatology clinics,
Isfahan, Iran in 2010. Patients were received this formula or placebo gels for the right
and left lesions. Lesion area and degree of pigmentation were assessed at baseline, 2, 4,
and 6 months.
Findings: There were no significant changes in lesion area and perifollicular pigmentation
in each group (P > 0.05).
Conclusion: The results indicated no significant therapeutic effect for PSD in vitiligo.
Keywords
- Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med
2009;360:160‑9.
2. Miniati A, Weng Z, Zhang B, Stratigos AJ, Nicolaidou E,
Theoharides TC. Neuro‑immuno‑endocrine processes
in vitiligo pathogenesis. Int J Immunopathol Pharmacol
2012;25:1‑7.
3. Patel NS, Paghdal KV, Cohen GF. Advanced treatment
modalities for vitiligo. Dermatol Surg 2012;38:381‑91.
4. Colucci R, Lotti T, Moretti S. Vitiligo: An update on current
pharmacotherapy and future directions. Expert Opin
Pharmacother 2012;13:1885‑99.
5. Hazneci E, Karabulut AB, Oztürk C, Batçioğlu K, Doğan G,
Karaca S, et al. A comparative study of superoxide dismutase,
catalase, and glutathione peroxidase activities and nitrate
levels in vitiligo patients. Int J Dermatol 2005;44:636‑40.
6. Arican O, Kurutas EB. Oxidative stress in the blood of patients
with active localized vitiligo. Acta Dermatovenerol Alp
Panonica Adriat 2008;17:12‑6.
7. Gawkrodger DJ. Pseudocatalase and narrowband ultraviolet B
for vitiligo: Clearing the picture. Br J Dermatol 2009;161:721‑2.
8. Yuksel EP, Aydin F, Senturk N, Canturk T, Turanli AY.
Comparison of the efficacy of narrow band ultraviolet B and
narrow band ultraviolet B plus topical catalase‑superoxide
dismutase treatment in vitiligo patients. Eur J Dermatol
2009;19:341‑4.
9. Bakis‑Petsoglou S, Le Guay JL, Wittal R. A randomized,
double‑blinded, placebo‑controlled trial of pseudocatalase
cream and narrowband ultraviolet B in the treatment of
vitiligo. Br J Dermatol 2009;161:910‑7.
10. Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella
R. A double‑blind, randomized trial of 0.05% betamethasone
vs. topical catalase/dismutase superoxide in vitiligo. J Eur
Acad Dermatol Venereol 2008;22:1359‑64. - 11. Schallreuter KU, Rokos H. Vitix‑ A new treatment for vitiligo?
Int J Dermatol 2005;44:969‑70.
12. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for
the treatment of vitilgo vulgaris: An open label pilot clinical
trial. BMC Complement Altern Med 2011;11:21
)